» Articles » PMID: 21466650

Reduced-dose Tacrolimus with Mycophenolate Mofetil Vs. Standard-dose Tacrolimus in Liver Transplantation: a Randomized Study

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2011 Apr 7
PMID 21466650
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

We conducted a multicenter randomized study in liver transplantation to compare standard-dose tacrolimus to reduced-dose tacrolimus with mycophenolate mofetil to reduce the occurrence of tacrolimus side effects. Two primary outcomes (censored criteria) were monitored during 48 weeks post-transplantation: occurrence of renal dysfunction or arterial hypertension or diabetes (evaluating benefit) and occurrence of acute graft rejection (evaluating risk). Interim analyses were performed every 40 patients to stop the study in the case of increased risk of graft rejection. One hundred and ninety-five patients (control: 100; experimental: 95) had been included when the study was stopped. Acute graft rejection occurred in 46 (46%) and 28 (30%) patients in control and experimental groups, respectively (HR = 0.59; 95% CI: [0.37-0.94]; p = 0.024). Renal dysfunction or arterial hypertension or diabetes occurred in 80 (80%) and 61 (64%) patients in control and experimental groups, respectively (HR = 0.68; 95% CI: [0.49-0.95]; p = 0.021). Renal dysfunction occurred in 42 (42%) and 23 (24%) patients in control and experimental groups, respectively (HR = 0.49; 95% CI: [0.29-0.81]; p = 0.004). Leucopoenia (p = 0.001), thrombocytopenia (p = 0.017) and diarrhea (p = 0.002) occurred more frequently in the experimental group. Reduced-dose tacrolimus with mycophenolate mofetil reduces the occurrence of renal dysfunction and the risk of graft rejection. This immunosuppressive regimen could replace full-dose tacrolimus in adult liver transplantation.

Citing Articles

Reconstructive Surgery of the Head and Neck in Organ Transplant Recipients: A Case Report and a Review of the Literature.

Rampi A, Comini L, Galli A, Howardson B, Tettamanti A, Luparello P J Clin Med. 2024; 13(16).

PMID: 39200933 PMC: 11355776. DOI: 10.3390/jcm13164790.


Estimation of lifetime costs for patients receiving a transplant: the case of liver transplantation related to hepatitis B in Italy.

Marzano A, Canali B, De Carlis L, De Simone P, Fiorentino F, Rendina M Front Public Health. 2024; 12:1328782.

PMID: 39026594 PMC: 11256195. DOI: 10.3389/fpubh.2024.1328782.


Post Liver Transplant Renal Dysfunction-Evaluation, Management and Immunosuppressive Practice.

Raja K, Panackel C J Clin Exp Hepatol. 2024; 14(2):101306.

PMID: 38274509 PMC: 10806298. DOI: 10.1016/j.jceh.2023.101306.


Long Term Complications of Immunosuppression Post Liver Transplant.

Mehtani R, Saigal S J Clin Exp Hepatol. 2023; 13(6):1103-1115.

PMID: 37975039 PMC: 10643541. DOI: 10.1016/j.jceh.2023.06.007.


Impact of Sirolimus versus Mycophenolate Mofetil on Kidney Function after Calcineurin Inhibitor Dose Reduction in Liver Transplant Recipients.

Chiang H, Li L, Hsu C, Lin C, Chan Y, Wang C Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631002 PMC: 10457954. DOI: 10.3390/ph16081087.